Martin H. Voss

Oncology
353 E 68th St
New York, NY 10065

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 154 publications

Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma.

Complete response to dual immune checkpoint blockade in a patient with Birt-Hogg-Dubé syndrome and epithelioid angiomyolipoma.

Journal: Journal for immunotherapy of cancer
Published: July 17, 2026

Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management.

Expanding the phenotype of hereditary renal cell carcinoma syndromes: Implications for surveillance and management.

Journal: Journal of the National Cancer Institute
Published: April 13, 2026

From diversity to function: microbiome precision in RCC.

From diversity to function: microbiome precision in RCC.

Journal: Nature reviews. Urology
Published: April 08, 2026

Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

Panitumumab-Based EGFR Blockade in SMARCB1-Deficient Renal Medullary Carcinoma: Preclinical Basis and Prospective Clinical Activity.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: January 27, 2026

Mechanistic insights make cancer cachexia a targetable syndrome.

Mechanistic insights make cancer cachexia a targetable syndrome.

Journal: Nature medicine
Published: January 02, 2026

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Journal: CA: a cancer journal for clinicians
Published: September 15, 2025

Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma.

Pathologic Response to Immunotherapy Is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma.

Journal: European urology oncology
Published: June 05, 2025

Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone.

Long-term oncologic outcomes of metastatic clear-cell renal cell carcinoma after local therapy alone.

Journal: Urologic oncology
Published: June 04, 2025

Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma.

Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma.

Journal: Urologic oncology
Published: May 30, 2025

MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma.

MLH1 Mismatch Repair Deficiency Predicts Exceptional Response to Immune Checkpoint Inhibition in Clear-cell Renal Cell Carcinoma.

Journal: European urology
Published: May 18, 2025

Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.

Developing biomarkers and methods of risk stratification: Consensus statements from the International Kidney Cancer Symposium North America 2024 Think Tank.

Journal: Urologic oncology
Published: May 12, 2025

Pathologic Response to Immunotherapy is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma.

Pathologic Response to Immunotherapy is Associated with Survival in Patients Undergoing Delayed Nephrectomy for Metastatic Renal Cell Carcinoma.

Journal: medRxiv : the preprint server for health sciences
Published: May 02, 2025
Showing 1-12 of 154

Last Updated: 09/26/2026